News

In a recent study presented during the European League Against Rheumatism Annual European Congress of Rheumatology, patients with gastrointestinal symptoms associated with systemic sclerosis may benefit from IV immunoglobulin therapy treatment. For the study, Raja J. and colleagues recruited 15 patients with a diagnosis of systemic sclerosis (SSc) from the…

A collaboration between Bristol-Myers Squibb Company and The Medical University of South Carolina (MUSC) will focus on translational research for developing scleroderma and other fibrotic disease treatments. The goal is to combine the two teams’ expertise to advance exciting new research into effective therapeutic options for patients with fibrotic disease.

Patients in the LOTUSS study who were treated for systemic sclerosis-associated idiopathic pulmonary fibrosis (SSc-IPF) using Esbriet (pirfenidone) showed signs of drug tolerability, according to a presentation at the European League Against Rheumatism (EULAR) 2015 congress held in Rome. Esbriet, which was approved by the Food and…

Digital ulcers, or open sores on the fingers and toes that do not heal, are common complications of systemic sclerosis. Approximately 30% of patients with systemic sclerosis have digital ulcers, most commonly on the fingertips or on the elbows due to taut skin or trauma. These painful sores can lead…

In a recent study published in the journal Arthritis Research & Therapy, a team of researchers from Germany uncovered new insights into PAH detection in Scleroderma patients, determining that PH-screening using echocardiography in systemic sclerosis patients should be performed at rest and during exercise. Pulmonary hypertension (PH) is…

Autoimmune conditions can sometimes come in pairs, and it appears that individuals for systemic sclerosis (SSc) may also be at a risk for antiphospholipid antibody syndrome. A study from the Clinical Immunology Department of Colentina Clinical Hospital in Romania identified that patients with SSc commonly express antiphospholipid antibodies, although not…

A investigational drug being developed by Corbus Pharmaceuticals Holding, Inc. to treat systemic sclerosis was granted orphan drug designation by the U.S. Food and Drug Administration (FDA). The drug that received the status, resunab, is Corbus’ lead drug candidate, as the company is focused on…